Business
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) are posted at the American Academy of Neurology’s first-ever Sports Concussion Conference. The research was sponsored by Trigemina, Inc. In June 2020 Tonix acquired the assets of Trigemina, including certain rights to the data described in the presentation. The virtual meeting was held July 31, 2020 and August 1, 2020. The presentation can be found on the Scientific Presentations page of Tonix’s website.\n The presentation, titled “Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI),” includes data from a preclinical study which investigated the efficacy of intranasal oxytocin in relieving pain and associated depressive behavior following traumatic brain injury. The data show that intranasal oxytocin, but not intravenous oxytocin or vehicle, attenuated both reactive and spontaneous pain following mild traumatic brain injury in an animal model. Intranasal oxytocin was also shown to attenuate post-traumatic brain injury depressive and anxiety behaviors in the same animal model. These effects were blocked by the oxytocin receptor antagonist, Atosiban, indicating the effects of intranasal oxytocin were mediated by oxytocin receptors. Intranasal oxytocin was shown to result in high concentrations of oxytocin primarily in the trigeminal ganglia. “The preclinical data that we have seen to date show that intranasal oxytocin has the potential to be a treatment for pain and depressive behavior associated with traumatic brain injury headaches and post-concussion syndrome,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. About Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseas...